Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Healthcare · Biotechnology

Absci Corporation logoAbsci Corporation

ABSI · Nasdaq · USD · Market cap $1.6B · 140 employees

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.

FAIL · Does not pass the screen
7.58 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price7.58 USD at the 17 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 17 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.49)
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $10.00 to $16.90, base estimate $15.00 (screen dated 2026-11-17).

Current read
Markup ?
Undervalued · screened 2026-11-17
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.49, read 2026-11-13
  • Ethical does not pass the values gate
Price7.58 USD
Fair value15.00
Ethical score70.0/100
Value readUndervaluedas of 17 Nov 2026
Our investment reviews on this name
2026-11-01Read Markup11.13-31.9% to today Distribution gives way to Markup after a 19% rise in 7 days
2026-10-25Read Distribution9.37-19.1% to today ✓Markup gives way to Distribution
2026-10-11Read Markup9.22-17.8% to today Accumulation gives way to Markup after a 6% slide in 9 days
2026-10-02Read Accumulation9.82-22.8% to today Markdown gives way to Accumulation after a 6% rise in 13 days

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Absci Corporation holds its Markup at $7.58. The statistical read favours the sellers, held for 28 days.

As held on the ledger · 2026-11-17
PhaseMarkup
Quantitative stateThe statistical read favours the sellers, held for 28 days
Price at the screen$7.58
ValuationN/A trailing · -13.54 forward price to earnings
Values screenFAIL · score 70.0
Beta2.19
The Workings

Five Screens, Shown in Full

Does not pass. Interest-bearing securities

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 2.45% Below 33% Interest-bearing debt is just 2.5% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 57.45% Below 33% Interest-bearing cash and securities are 57.5% of assets, above the one-third limit. Fail
Receivables 9.26% Below 49% Money owed to the company is 9.3% of assets, under the 49% limit. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Absci's business is fine, but its cash and interest-bearing securities are about 57% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when ABSI's ethical verdict changes

Today ABSI does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued vs our fair value, as of 17 Nov 2026: it trades at roughly a 49% discount to our $15.00 fair value.

How a fair value is estimated: discounted cash flow (DCF).

10.00Conservative15.00Base case16.90Growth case 7.58Price

Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 49.5% discount to the base estimate.

The Street's Range
10.00Street low 15.00Street average 20.00Street high 7.58Price

Third-party analyst targets: 11 covering, consensus Strong Buy. The average target sits +98% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $15.00, with a range of $10.00 to $16.90, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Biotech dreams meet collapsing revenue reality

Every new antibody therapy starts with a scientist in a lab hoping one molecule will tame disease where others failed. Absci is chasing that bet across inflammatory conditions, yet its revenue has fallen 82% while it posts zero profit margins and a negative 64% return on equity. The market prices the shares well below our calculated fair value, but the business shows none of the durable traits that justify stepping in.

Analyst notes highlight a strong buy chorus and a $13 target, and the name clears our ethical screen without flags. Still, a forward price to earnings ratio of negative 13 times and an unknown competitive moat leave the story resting on future clinical wins that remain unproven. We see no reason to override those numbers.

Clinical development carries binary trial outcomes and repeated cash calls that can wipe out early gains in months. Currency and sector swings add further volatility to an already fragile setup. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-13.5x
EPS, trailing-0.79
EPS, forward-0.69
Revenue growth-46.4%revenue is shrinking
Profit margin0.0%currently unprofitable
Return on equity-57.7%not currently earning a positive return on equity
FCF yield-3.14%
Debt to equity1.56a meaningful debt load worth watching
Current ratio10.63comfortably covers its short-term bills
Beta2.19much more volatile than the market
Short interest, float0.26%
52-week range2.24 - 12.55
Market cap$1.6B
Employees140

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

ABSI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-12 Markup $10.12 +1.5% Entry 20

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-11 Markup $9.97 -7.7% Entry 19

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 7.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-10 Markup $10.80 +6.2% Entry 18

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-09 Markup $10.17 +0.0% Entry 17

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 73% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-08 Markup $10.17 +0.0% Entry 16

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-07 Markup $10.17 +8.3% Entry 15

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-06 Markup $9.39 -10.4% Entry 14

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 10.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-05 Markup $10.48 -5.8% Entry 13

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 5.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Markup · changed $11.13 +18.8% Entry 12

The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9.

2026-10-25 Distribution · changed $9.37 +5.5% Entry 11

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 5.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 67% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 121%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (9 analysts) rates it strong buy, with a mean price target of $9.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on ABSI

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in ABSI's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $5.78 +15.7% · $1,157 +15.7%
2 months $2.98 +124.5% · $2,245 +124.5%
3 months $2.30 +190.9% · $2,909 +190.9%
6 months $3.84 +74.2% · $1,742 +74.2%
1 year $3.03 +120.8% · $2,208 +120.8%
2 years $4.52 +48.0% · $1,480 +48.0%
3 years $1.68 +298.2% · $3,982 +298.2%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever ABSI does next, these words stay.

Absci Corporation · ABSI · Markup · $7.58
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.